Strong Revenue Growth
Total sales for the third quarter were approximately $338 million, representing a 6.7% growth year-over-year as reported and 6.3% growth in constant currency.
Key Product Performance
General surgery grew 6.9% globally on a constant currency basis, and orthopedics delivered 5.3% constant currency growth globally.
Operational Improvements
Record manufacturing volumes for orthopedic products and a significant reduction in critical SKUs, indicating progress in supply chain improvements.
Strategic Portfolio Review
Engagement with top-tier consultants to assess product offerings, focusing on long-term return on invested capital and improving margin profile.
Share Repurchase Program
Board authorized a new $150 million share repurchase program, transitioning from legacy dividend policy to prioritize shareholder value.